English

Report on operations 2015: Continued profitable growth

Report this content

Fourth quarter:

  • Sales amounted to SEK 199 (137) million, corresponding to an increase of 45 percent in SEK. Net sales growth was 38 percent in local currency.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 81 (44) million, corresponding to a margin of 41 (32) percent.
  • Net income amounted to SEK 57 (28) million, which gave earnings per share of SEK 2.63 (1.39).

Whole year 2015:

  • Sales amounted to SEK 722 (511) million, corresponding to an increase of 41 percent in SEK. Net sales growth was 28 percent in local currency.
  • Operating income before depreciation and amortization (EBITDA) amounted to SEK 279 (167) million, corresponding to a margin of 39 (33) percent.
  • Net income amounted to SEK 183 (109) million, which gave earnings per share of SEK 8.42 (5.46).

After the end of the year:

  • The Board proposes a dividend of SEK 2.40 (1.50) per share.
  • Decision to consolidate the Group’s time-lapse business to the subsidiary Vitrolife A/S in Denmark during 2016.

Gothenburg, February 5, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on February 5, 2016 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

Vitrolife fertility IVF telephone conference interim report Mikael Engblom Thomas Axelsson

Subscribe

Documents & Links